CSTLCASTLE BIOSCIENCES INC

Nasdaq castlebiosciences.com


$ 23.52 $ -0.26 (-1.07 %)    

Wednesday, 08-May-2024 15:59:49 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 23.54
$ 23.20
$ 0.00 x 0
$ 0.00 x 0
$ 23.16 - $ 23.97
$ 9.26 - $ 26.70
176,531
na
647M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-10-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 09-03-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-outperform-on-castle-biosciences-raises-price-target-to-34

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...

 castle-biosciences-q1-2024-gaap-eps-009-beats-033-estimate-sales-72974m-beat-66199m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(...

 castle-biosciences-gives-long-term-outcomes-data-shared-at-sso-2024-show-that-patients-with-a-low-risk-decisiondx-melanoma-test-result-were-recurrence-free-at-3-years-including-those-who-utilized-the-test-to-help-guide-the-decision-to-avoid-an-slnb

Castle's second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical u...

 castle-biosciences-new-study-showing-the-drug-drug-interactions-and-lifestyle-factors-provided-by--idgenetix-test-improve-medication-recommendations-over-drug-gene-interactions-alone-for-patients-65-and-older

Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifest...

 castle-biosciences-to-present-new-data-highlighting-the-clinical-value-of-its-dermatologic-tests-for-patients-with-skin-cancer-at-the-2024-american-academy-of-dermatology-annual-meeting

Castle's presentations at AAD include the latest findings from the Company's ongoing collaboration with the National Ca...

 keybanc-maintains-overweight-on-castle-biosciences-raises-price-target-to-28

Keybanc analyst Paul Knight maintains Castle Biosciences (NASDAQ:CSTL) with a Overweight and raises the price target from $2...

 scotiabank-maintains-sector-outperform-on-castle-biosciences-raises-price-target-to-37

Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and raises the price targ...

 why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

 castle-biosciences-q4-2023-gaap-eps-010-beats-061-estimate-sales-6612m-beat-5628m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(...

 earnings-scheduled-for-february-28-2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION